Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea

Biochimica et Biophysica Acta - General Subjects

Volumn 1622, Issue 2, 2003, Pages 109-116

  Lockamy, Virginia L ^a   Huang, Jinming ^a   Shields, Howard ^a   Ballas, Samir K ^b   King, S Bruce ^a   Kim Shapiro, Daniel B ^a  

^a WAKE FOREST UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Hydroxylamine; Hydroxyurea; Nitric oxide; Sickle cell disease

Indexed keywords

HEMOGLOBIN; HYDROXYLAMINE; HYDROXYUREA; IRON NITROSYL HEMOGLOBIN; NITRIC OXIDE; UNCLASSIFIED DRUG; UREASE;

ARTICLE; BLOOD COMPONENT; CELL VOLUME; CHEMICAL INTERACTION; CHEMICAL REACTION; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE;

EID: 0037767672     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(03)00132-6     Document Type: Article

References (47)

1. Dressler W.F.C., Stein R. Ueber den Hydroxyharnstoff. Justus Liebigs Ann. Chem. Pharmacol. 150:1869;242-252.
2. Yarbo J.W. Further studies on the mechanism of action of hydroxyurea. Cancer Res. 28:1992;1082-1087.
3. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., McMahon R.P., Bonds D.R. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332:1995;1317-1322.
4. Cokic V.P., Smith R.D., Beleslin-Cokic B.B., Njoroge J.M., Miller J.L., Gladwin M.T., Schechter A.N. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 111:2003;231-239.
5. Charache S., Barton F.B., Moore R.D., Terrin M.L., Steinberg M.H., Dover G.J., Ballas S.K., McMahon P., Oswaldo C., Orringer E.P. Hydroxyurea and sickle cell anemia. Medicine. 75:1996;300-326.
6. Stolze K., Nohl H. EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin. Biochem. Pharmacol. 40:1990;799-802.
7. Stolze K., Nohl H. Reactions of reducing xenobiotics with oxymyoglobin, ferryl myoglobin and free radicals: an electron spin resonance and chemiluminescence study. Biochem. Pharmacol. 49:1995;1261-1267.
8. Gladwin M.T., Schechter A.N. Nitric oxide therapy in sickle cell disease. Semin. Hematol. 38:2001;333-342.
9. Pacelli R., Taira J., Cook J.A., Wink D.A., Krishna M.C. Hydroxyurea reacts with heme proteins to produce nitric oxide. Lancet. 347:1996;900.
10. Kim-Shapiro D.B., King S.B., Bonifant C.L., Ballas S.K. Time-resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Biochim. Biophys. Acta. 1380:1998;64-74.
11. Kim-Shapiro D.B., King S.B., Shields H., Kolibash C.P., Gravatt W.L., Ballas S.K. The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Biochim. Biophys. Acta. 1428:1999;381-387.
12. Xu Y., Mull C.D., Bonifant C.L., Yasaki G., Palmer E.C., Shields H., Ballas S.K., Kim-Shapiro D.B., King S.B. Nitrosylation of sickle cell hemoglobin by hydroxyurea. J. Org. Chem. 63:1998;6452-6453.
13. Huang J., Hadimani S.B., Rupon J.W., Ballas S.K., Kim-Shapiro D.B., King S.B. Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea. Biochem. 41:2002;2466-2474.
14. Jiang J., Jordan S.J., Barr D.P., Gunther M.R., Maeda H., Mason R.P. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol. Pharmacol. 52:1997;1081-1086.
15. Glover R.E., Ivy E.D., Orringer E.P., Maeda H., Mason R.P. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea. Mol. Pharmacol. 55:1999;1006-1010.
16. Gladwin M.T., Shelhamer J.H., Ognibene F.P., Pease-Frye M.E., Nichols J.S., Link B., Patel D.B., Jankowski M.A., Pannell L.K., Schechter A.N., Rodgers G.P. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br. J. Haematol. 116:2002;436-444.
17. Nahavandi M., Wyche M.Q., Perlin E., Castro O., Tavakkoli F. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea. Hematology. 5:2000;335-339.
18. Nahavandi M., Tavakkoli F., Wyche M.Q., Perlin E., Winter W.P., Castro O. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br. J. Haematol. 199:2002;855-857.
19. Nahavandi M., Perlin E., Kassim O.O., Wyche M.Q., Castro O., Tavakkoli F. Upregulation of TNFα by hydroxyurea in patients with sickle cell anemia. Blood. 96(Suppl. 1):2000;44a.
20. Morris C.R., Kuypers F.A., van Warmerdam J., Machado L., Larkin S., Vichinsky E.P. A nitric oxide synthase mechanism for hydroxyurea? Blood. 98(Suppl. 1):2001;487a.
21. Morris C.R., Vichinsky E.P., van Warmerdam J., Machado L., Larkin S., Kuypers F.A. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. Blood. 98(Suppl. 1):2001;785a.
22. Bazylinski D.A., Arkowitz R.A., Hollocher T.C. Decomposition of hydroxylamine by hemoglobin. Arch. Biochem. Biophys. 259:1987;520-526.
23. Stolze K., Nohl H. Detection of free radicals as intermediates in the methemoglobin formation from oxyhemoglobin induced by hydroxylamine. Biochem. Pharmacol. 38:1989;3055-3059.
24. Stolze K., Nohl H. EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin. Biochem. Pharmacol. 40:1990;799-802.
25. Stolze K., Nohl H. Reactions of reducing xenobiotics with oxymyoglobin, ferryl myoglobin and free radicals: an electron spin resonance and chemiluminescence study. Biochem. Pharmacol. 49:1995;1261-1267.
26. Fishbein W.N., Carbone P.P. Hydroxyurea: mechanism of action. Science. 142:1963;1069-1070.
27. Fishbein W.N., Winter T.S., Davidson J.D. Urease catalysis: I. Stoichometry, specificity, and kinetics of a second substrate: hydroxyurea. J. Biol. Chem. 240:1965;2402-2406.
28. Huang Z., Louderback J.G., Azizi F., Goyal M., King S.B., Kim-Shapiro D.B. Nitric oxide binding to hemoglobin under physiological conditions. Biochim. Biophys. Acta. 1568:2001;252-260.
29. Xu X., Lockamy V.L., Chen K., Huang Z., Shields H., King S.B., Ballas S.K., Nichols J.S., Gladwin M.T., Noguchi C.T., Schechter A.N., Kim-Shapiro D.B. Effects of iron nitrosylation on sickle cell hemoglobin solubility. J. Biol. Chem. 277:2002;36787-36792.
30. Hille R., Olson J.S., Parker G. Spectral transitions of nitrosyl hemes during ligand binding to hemoglobin. J. Biol. Chem. 254:1979;12110-12120.
31. Di Iorio E.E. Preparation of derivatives of ferrous and ferric hemoglobin. Methods Enzymol. 76:1981;57-87.
32. Hampl V., Walters C.L., Archer S.L. Determination of nitric oxide by the chemiluminescence reaction with ozone. Feelisch M., Stamler J.S. Methods in Nitric Oxide Research. 1996;309-318 Wiley, New York, NY.
33. Arnold E.V., Bohle D.S. Isolation and oxygenation reactions of nitrosylmyoglobins. Methods Enzymol. 269:1996;41-55.
34. Sharma V.S., Ranney H.R. The dissociation of NO from nitrosylhemoglobin. J. Biol. Chem. 253:1978;6467-6472.
35. Fishbein W.N., Carbone P.P. Urease catalysis: II. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid. J. Biol. Chem. 240:1965;2407-2414.
36. Donehower R.C. Hydroxyurea. Chabner B.A., Longo D.L. Cancer Chemotherapy and Biotherapy. 1996;253-261 Lippincott-Raven, Philadelphia, PA.
37. Charache S., Dover G., Moore R.D., Eckert S., Ballas S.K., Koshy M., Milner P.F.A., Orringer E.P., Phillips G. Jr., Platt O.S., Thomas G.H. Hydroxyurea - effects on hemoglobin F production in patients with sickle cell anemia. Blood. 79:1992;2555-2565.
38. Woods K.F., Onuooha A., Schade R.R., Kutlar A. Heliobacter pylori infection in sickle cell disease. J. Natl. Med. Assoc. 92:2000;361-365.
39. Epidemiology of, and risk factors for, Heliobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut. 34:1993;1672-1676.
40. Dominici P., Bellentani S., Di Biase A.R., Saccoccio G., Le Rose A., Masutti F., Viola L., Balli F., Tiribelli C., Grilli R., Fusillo M., Grossi E. Familial clustering of Heliobacter pylori infection: population based study. Br. Med. J. 319:1999;537-540.
41. Malaty H.M., Evans D.G. Jr., Graham D.Y. Heliobacter pylori in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology. 103:1992;813-816.
42. Rodgers G.P. Stimulation of fetal hemoglobin synthesis using pharmacological agents - update on the NIH experience. Proceeding of the 21st Annual Meeting of the National Sickle Cell Disease Program, Mobile, Alabama. 1996;040. abstract.
43. Gwilt P.R., Tracewell W.G. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet. 34:1998;347-358.
44. Aslan M., Ryan T.M., Adler B., Townes T.M., Parks D.A., Thompson J.A., Tousson A., Gladwin M.T., Patel R.P., Tarpey M.M., Batinic-Haberle I., White C.R., Freeman B.A. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5215-15220.
45. Reiter C.D., Wang X.D., Tanus-Santos J.E., Hogg N., Cannon R.O., Schechter A.N., Gladwin M.T. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8:2002;1383-1389.
46. Sakano K., Oikawa S., Hiraku Y., Kawanishi S. Metabolism of carcinogenic urethane to nitric oxide is involved in oxidative DNA damage. Free Radic. Biol. Med. 33:2002;703-714.
47. Wang P.G., Xian M., Tang X., Wu X., Wen Z., Cai T., Janczuk A.J. Nitric oxide donors: chemical activities and biological applications. Chem. Rev. 102:2002;1091-1134.